Search research articles
Contact Us
Filters
Showing results (131-140 of 175) with videos related to
Page
of 18
Sort By:
The New England Journal of Medicine
|
August 17, 2012
Increased survival with enzalutamide in prostate cancer after chemotherapy
Howard I Scher, Karim Fizazi, Fred Saad, et al.
Molecular Oncology
|
June 11, 2019
AR splice variants in circulating tumor cells of patients with castration-resistant prostate cancer: relation with outcome to cabazitaxel
Anieta M Sieuwerts, Wendy Onstenk, Jaco Kraan, et al.
The Lancet. Oncology
|
September 14, 2020
Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide (CARD): an analysis of a randomised, multicentre, open-label, phase 4 study
Karim Fizazi, Gero Kramer, Jean-Christophe Eymard, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 26, 2021
Initial Management of Noncastrate Advanced, Recurrent, or Metastatic Prostate Cancer: ASCO Guideline Update
Katherine S Virgo, R Bryan Rumble, Ronald de Wit, et al.
The New England Journal of Medicine
|
February 18, 2017
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
Joaquim Bellmunt, Ronald de Wit, David J Vaughn, et al.
Cancer
|
October 28, 2024
Efficacy and safety of pembrolizumab in patients with advanced urothelial carcinoma deemed potentially ineligible for platinum-containing chemotherapy: Post hoc analysis of KEYNOTE-052 and LEAP-011
Peter H O'Donnell, Yohann Loriot, Tibor Csoszi, et al.
The Lancet. Oncology
|
March 7, 2015
Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trial
Daniel P Petrylak, Nicholas J Vogelzang, Nikolay Budnik, et al.
BMC Gastroenterology
|
February 13, 2021
Diagnostic yield of colonoscopy surveillance in testicular cancer survivors treated with platinum-based chemotherapy: study protocol of a prospective cross-sectional cohort study
Berbel L M Ykema, Tanya M Bisseling, Manon C W Spaander, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 7, 2021
Anti-PD-1 Efficacy in Patients with Metastatic Urothelial Cancer Associates with Intratumoral Juxtaposition of T Helper-Type 1 and CD8<sup>+</sup> T cells
Maud Rijnders, Hayri E Balcioglu, Debbie G J Robbrecht, et al.
European Urology
|
October 1, 2023
Pembrolizumab with or Without Lenvatinib as First-line Therapy for Patients with Advanced Urothelial Carcinoma (LEAP-011): A Phase 3, Randomized, Double-Blind Trial
Nobuaki Matsubara, Ronald de Wit, Arjun Vasant Balar, et al.
Page
of 18
Search research articles
Search
Showing results (131-140 of 175) with videos related to
Sort By:
Page
of 18
The New England Journal of Medicine
|
August 17, 2012
Increased survival with enzalutamide in prostate cancer after chemotherapy
Howard I Scher, Karim Fizazi, Fred Saad, et al.
Molecular Oncology
|
June 11, 2019
AR splice variants in circulating tumor cells of patients with castration-resistant prostate cancer: relation with outcome to cabazitaxel
Anieta M Sieuwerts, Wendy Onstenk, Jaco Kraan, et al.
The Lancet. Oncology
|
September 14, 2020
Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide (CARD): an analysis of a randomised, multicentre, open-label, phase 4 study
Karim Fizazi, Gero Kramer, Jean-Christophe Eymard, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 26, 2021
Initial Management of Noncastrate Advanced, Recurrent, or Metastatic Prostate Cancer: ASCO Guideline Update
Katherine S Virgo, R Bryan Rumble, Ronald de Wit, et al.
The New England Journal of Medicine
|
February 18, 2017
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
Joaquim Bellmunt, Ronald de Wit, David J Vaughn, et al.
Cancer
|
October 28, 2024
Efficacy and safety of pembrolizumab in patients with advanced urothelial carcinoma deemed potentially ineligible for platinum-containing chemotherapy: Post hoc analysis of KEYNOTE-052 and LEAP-011
Peter H O'Donnell, Yohann Loriot, Tibor Csoszi, et al.
The Lancet. Oncology
|
March 7, 2015
Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trial
Daniel P Petrylak, Nicholas J Vogelzang, Nikolay Budnik, et al.
BMC Gastroenterology
|
February 13, 2021
Diagnostic yield of colonoscopy surveillance in testicular cancer survivors treated with platinum-based chemotherapy: study protocol of a prospective cross-sectional cohort study
Berbel L M Ykema, Tanya M Bisseling, Manon C W Spaander, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 7, 2021
Anti-PD-1 Efficacy in Patients with Metastatic Urothelial Cancer Associates with Intratumoral Juxtaposition of T Helper-Type 1 and CD8<sup>+</sup> T cells
Maud Rijnders, Hayri E Balcioglu, Debbie G J Robbrecht, et al.
European Urology
|
October 1, 2023
Pembrolizumab with or Without Lenvatinib as First-line Therapy for Patients with Advanced Urothelial Carcinoma (LEAP-011): A Phase 3, Randomized, Double-Blind Trial
Nobuaki Matsubara, Ronald de Wit, Arjun Vasant Balar, et al.
Page
of 18